美國居民不適用 XM 服務。
H
H

Hologic


財經新聞

U.S. STOCKS Tempus AI, AeroVironment, Gold miners

BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, AeroVironment, Gold miners Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes were flat on Thursday, as investors assessed a string of economic data ahead of the Federal Reserve's closely watched inflation report, while Micron and pharmacy chain Walgreens Boots Alliance slumped on disappointing forecasts.
B
G
H
M
N
S
W
U
U
T
C
M

U.S. STOCKS Verona Pharma, McCormick, gold miners

BUZZ-U.S. STOCKS ON THE MOVE-Verona Pharma, McCormick, gold miners Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq slightly fell while other indexes were flat to slightly higher on Thursday, as a dip in Treasury yields after a string of economic data boosted megacap stocks.
B
G
H
M
S
W
U
U
T
M

U.S. STOCKS Elanco Animal Health, Levi Strauss, SM Energy

BUZZ-U.S. STOCKS ON THE MOVE-Elanco Animal Health, Levi Strauss, SM Energy Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures slipped on Thursday as a slump in Micron Technology after a lackluster forecast dragged down other semiconductor stocks, while caution ahead of economic data and a presidential debate also dented sentiment.
H
M
W
U
T

U.S. STOCKS International Paper, U.S. Bancorp, Micron Technology

BUZZ-U.S. STOCKS ON THE MOVE-International Paper, U.S. Bancorp, Micron Technology Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures slipped on Thursday as a slump in Micron Technology after a lackluster forecast dragged down other semiconductor stocks, while caution ahead of economic data and a presidential debate also dented sentiment.
H
M
W
U

Stephens starts Hologic with 'overweight' on balance sheet, M&A potential

BUZZ-Stephens starts Hologic with 'overweight' on balance sheet, M&A potential ** Stephens starts Hologic HOLX.O with "overweight", citing the women's health diagnostic equipment maker's strong balance sheet, low leverage ratio and potential for M&A ** Sets TP of $87 vs stock's last close of $72.27; stock flat in premarket trading ** "With leverage
H

U.S. Carnival, FedEx, Micron Technology

U.S. RESEARCH ROUNDUP-Carnival, FedEx, Micron Technology June 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Carnival, FedEx and Micron Technology, on Thursday. HIGHLIGHTS * Carnival Corp CCL.N : Macquarie raises target price to $25 from $24 * FedEx Corp FDX.N : Daiwa Capital Markets raises target price to $318 from $296 * Micron Technology Inc MU.O : JP Morgan raises target price to $180 from $130 * Unifirst Cor
A
E
G
H
H
M
N
S
A
C
C
E

Australia's Lumos Diagnostics jumps on $5 mln payment

BUZZ-Australia's Lumos Diagnostics jumps on $5 mln payment ** Shares of Lumos Diagnostics LDX.AX rise as much as 21.6% to A$0.045, set for its best day since Jan. 11 if gains hold ** Healthcare tech co says it has received a second payment of US$5.0 million from Hologic HOLX.O under the intellectual property (IP) agreement announced on 11 Jan. ** I
H

FDA classifies recall of Hologic's implant as 'most serious'

UPDATE 1-FDA classifies recall of Hologic's implant as 'most serious' Adds detail and background in paragraphs 2 to 6 May 22 (Reuters) - The U.S. Food and Drug Administration on Wednesday classified a recall of Hologic's HOLX.O devices that are implanted in soft tissue such as breast tissue as "most serious", and urged doctors to more actively monitor for side-effects.
H

FDA classifies recall of Hologic's implants for soft tissue as 'most serious'

FDA classifies recall of Hologic's implants for soft tissue as 'most serious' May 22 (Reuters) - The U.S. Food and Drug Administration on Wednesday classified a recall of Hologic's HOLX.O devices that are implanted in soft tissue such as breast tissue as "most serious". Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber
H

U.S. Paramount Global, Sprout Social, Williams-Sonoma

U.S. RESEARCH ROUNDUP- Paramount Global, Sprout Social, Williams-Sonoma May 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Paramount Global, Sprout Social and Williams-Sonoma ,on Friday. HIGHLIGHTS * Expedia Group Inc EXPE.O : Piper Sandler cuts to neutral from overweight * Paramount Global PARA.O : Seaport Research Partners cuts to neutral from buy * Sprout Social Inc SPT.O : Piper Sandler cuts to neutral from ov
A
A
B
B
C
E
F
H
S
D
T
B
Z
A
B
C
M
T

Hologic posts upbeat second quarter profit

Hologic posts upbeat second quarter profit May 2 (Reuters) - Medical tech company Hologic HOLX.O reported second-quarter profit that beat Wall Street estimates on Thursday, sending its shares up 2.8% in extended trading. The Marlborough, Massachusetts-based company manufactures and supplies diagnostic tests and assays, medical imaging systems, and surgical products for women's healthcare.
H

Hologic Inc reports results for the quarter ended in March - Earnings Summary

Hologic Inc reports results for the quarter ended in March - Earnings Summary Hologic Inc HOLX.OQ reported quarterly adjusted earnings of $1.03​​ per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of $1.06. The mean expectation of fifteen analysts for the quarter was for earnings of 98 cents per share.
H

Hologic Q2 Adjusted EBITDA USD 335.6 Million Vs. IBES Estimate USD 324.5 Million

BRIEF-Hologic Q2 Adjusted EBITDA USD 335.6 Million Vs. IBES Estimate USD 324.5 Million May 02 (Reuters) - Hologic Q2 revenue USD 1,017.8 million vs. IBES estimate USD 1,002 million. Q2 gross margin 53.3% Q2 adjusted gross margin 60.7% Q2 operating margin 20.7% Q2 net income USD 169.9 million Q2 adjusted operating margin 30.4% Q2 adjusted net income USD 244.1 million vs.
H

Fed QT taper calms the horses, yen pops again

MORNING BID AMERICAS-Fed QT taper calms the horses, yen pops again A look at the day ahead in U.S. and global markets from Mike Dolan Anxious bond traders seem to have taken solace from the Federal Reserve's surprisingly sharp brake on its "quantitative tightening" process on Wednesday, while the yen capitalized on an easier dollar after what seemed like the second bout of Japanese intervention this week.
A
A
A
C
E
H
I
R
S
U
A
U
I
V
W
Z
A
B
D
H
I
L
P
P
P
T

Hologic Inc <HOLX.OQ> expected to post earnings of 98 cents a share - Earnings Preview

Hologic Inc expected to post earnings of 98 cents a share - Earnings Preview Hologic Inc HOLX.OQ HOLX.O is expected to show a fall in quarterly revenue when it reports results on May 2 for the period ending March 31 2024 The Marlborough Massachusetts-based company is expected to report a 2.4% decrease in revenue to $1.002 billion from $1.03 billion a year ago, according to the mean estimate from 13 analysts, based on LSEG data.The company's guidance on February 1 2024, for the period ended Mar
H

Hologic To Acquire Endomagnetics Ltd, A Breast Surgical Guidance Company

BRIEF-Hologic To Acquire Endomagnetics Ltd, A Breast Surgical Guidance Company April 29 (Reuters) - Hologic Inc HOLX.O : HOLOGIC TO ACQUIRE ENDOMAGNETICS LTD, A BREAST SURGICAL GUIDANCE COMPANY HOLOGIC INC - PROPOSED DEAL FOR FOR APPROXIMATELY $310 MILLION HOLOGIC- DEAL EXPECTED TO BE SLIGHTLY DILUTIVE TO HOLOGIC'S NON-GAAP EARNINGS PER SHARE IN FI
H



細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明